Increasing evidence suggests that tissue inhibitor of metalloproteinases-1 (TIMP-1) can directly regulate cell growth and apoptosis independent of its matrix metalloproteinases (MMPs)-inhibitory activity. While TIMP-1's antiapoptotic activity has been well demonstrated, conflicting data has been reported regarding TIMP-1's role in growth regulation. Here we show that TIMP-1 reduces the growth rate of human breast epithelial (MCF10A) cells by inducing cell cycle arrest at G 1 . TIMP-1-mediated cell cycle arrest is associated with its downregulation of cyclin D 1 and upregulation of p27 KIP1 , resulting in inhibition of cyclin-dependent kinase activity necessary for phosphorylation of the tumor suppressor retinoblastoma protein. We further show that TIMP-1 modulation of cyclin D 1 and p27 KIP1 is achieved through TIMP-1-mediated differential regulation of protein stability independent of growth factor signaling. We also show that TIMP-1-mediated differential regulation of cyclin D 1 and p27 KIP1 is independent of cell adhesion signaling. Whereas approximately 50% of MCF10A cells with reduced TIMP-1 expression underwent cell death following loss of cell adhesion (anoikis), TIMP-1 overexpressing cells remained viable with prominent cell cycle arrest without detectable cell death. Taken together, we propose that TIMP-1-mediated cell survival independent of cell adhesion is accompanied with cell cycle arrest in human breast epithelial cells, although cell cycle regulation may not be a prerequisite for TIMP-1 regulation of apoptosis in general.
Introduction
Development and maintenance of the mammary gland require timely and spatially regulated cell proliferation, adhesion, migration, polarization, differentiation, and apoptosis of mammary epithelial cells. These fundamental cellular processes are finely regulated by the interplay of signal transduction pathways mediated by growth factors, cell adhesion molecules and extracellular matrix (ECM) components (Dulbecco et al., 1986; Barcellos-Hoff et al., 1989; Damsky and Werb, 1992; Schmidt et al., 1993; Drubin and Nelson, 1996) . ECMdegrading enzymes and their inhibitors are indirectly involved in the outside-in signal transduction via their regulation of ECM turnover and remodeling, release of growth factors from ECM, and activation or inactivation of growth factors and their cell surface receptors (Juliano and Haskill, 1993; Fowlkes et al., 1994; Frisch and Francis, 1994; Roskelley et al., 1994; Lelievre et al., 1996; Whitelock et al., 1996) . Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) are among the ECM degrading enzymes and their inhibitors critical for mammary gland morphogenesis. Deregulation of levels and/or activities of these enzymes and inhibitors were shown to result in disruption of normal breast epithelial architecture (Fata et al., 1999; Sternlicht et al., 1999; Wiseman et al., 2003) .
TIMP-1, the founding member of the TIMP family (TIMPs-1 to -4), was discovered about two decades ago as a MMP inhibitor with its identity to the erythroidpotentiating activity (EPA) protein, a humoral factor that enhances the proliferation of human erythroid progenitors and certain cancer cells (Docherty et al., 1985; Gasson et al., 1985) (Bertaux et al., 1991; Hayakawa et al., 1992) . TIMP-1 expression is often enhanced at the early stages of carcinogenesis and confined to aggressive tumors including breast cancer (Yoshiji et al., 1996; Ree et al., 1997) . Association of TIMP-1 expression with poor prognosis of breast cancer (McCarthy et al., 1999; Schrohl et al., 2004) raises an important question regarding the role of TIMP-1 for the control of breast epithelial cell growth and death. Recently, we and others demonstrated that TIMP-1 inhibits breast epithelial cell apoptosis via induction of cell survival pathways (Guedez et al., 1998a, b; Li et al., 1999; Liu et al., 2003 Liu et al., , 2005 . TIMP-1 overexpression prevents human breast epithelial MCF10A cells from both polarization and apoptosis in three-dimensional matrigel culture, inhibiting formation of acini-like structures (Liu et al., 2005) . Since one of the hallmarks of breast cancer development/early progression is thought to be filling of the luminal space and disruption of the glandular epithelial structure, it would be of particular importance to understand the pleiotropic actions of TIMP-1 on breast epithelial cells. Interestingly, in contrary to TIMP-1-enhanced cell proliferation of some hematopoietic cells and certain cancer cells, TIMP-1 levels inversely correlate with mammary epithelial cell proliferation and ductal expansion in an animal model as demonstrated using slow-release pellets of recombinant TIMP-1 protein or transgenic antisense (AS) TIMP-1 RNA expression (Fata et al., 1999) . However, it is unclear whether TIMP-1 can directly regulate breast epithelial cell proliferation, and if so, how it regulates the cell cycle.
In this study, we show that TIMP-1 decreases cell proliferation of nonmalignant human breast epithelial MCF10A cells through cell cycle arrest at the G 1 phase. TIMP-1-mediated G 1 arrest is associated with upregulation of p27 KIP1 and downregulation of cyclin D 1 expression via differential regulation of protein stabilization. We also provide evidence suggesting that TIMP-1 regulation of protein stabilization may involve the proteasome pathway. Taking these results together with our previous finding, we propose that TIMP-1-mediated cell survival is accompanied with cell cycle arrest in human breast epithelial MCF10A cells.
Results
TIMP-1 levels inversely correlate with the rate of MCF10A cell proliferation To assess the role of TIMP-1 on human breast epithelial cell proliferation, we examined the growth rate of the previously established MCF10A clones engineered to modulate the levels of TIMP-1 expression. Generation of control vector-transfected MCF10A (Neo), TIMP-1 expression vector-transfected MCF10A clones #3 and #29 (T3 and T29) and AS TIMP-1 construct-transfected MCF10A clone (AS) was previously described (Li et al., 1999; Liu et al., 2003) . As expected from the parental MCF10A cells with the doubling time of approximately 24 h, the trypan blue exclusion assay ( Figure 1a ) revealed B10-fold increase in the cell number after 72 h culture of control Neo cells. In the same culture condition, only B5-fold increase was observed from T29 cells with TIMP-1 overexpression, whereas more than 20-fold increase was detected in AS cells with TIMP-1 downregulation. Consistently, WST-1 colorimetric assay (Figure 1b ) also showed the inverse correlation between the proliferation rates and the TIMP-1 expression levels.
TIMP-1 induces cell cycle arrest at G 1 To determine the mode of TIMP-1 regulation of cell proliferation, we examined the cell cycle phase distribution by flow cytometric DNA analysis. Whereas approximately 60% of Neo and AS cells were distributed to the G 1 phase after 24 h of plating as a monolayer, B75% of TIMP-1 overexpressing MCF10A cells (T3 and T29) were in the G 1 phase of the cell cycle (Figure 2 , left panels). It was noted that the TIMP-1-increased G 1 phase population was accompanied with decreased S phase.
Previously, we showed that TIMP-1 inhibits apoptosis induced by a variety of stimuli including anoikis, a specific form of apoptosis induced by loss of cell anchorage (Li et al., 1999; Liu et al., 2003 Liu et al., , 2005 . Since cells resistant to anoikis are often associated with their ability to induce cell cycle arrest, we asked if TIMP-1 inhibition of anoikis is also associated with its ability to regulate cell cycle. As shown in the right panels in Figure 2 , whereas B24% of Neo cells were found in the dying cell population sub-G 0 /G 1 following 24 h of suspension culture, more than 44% of AS cells were in the sub-G 0 /G 1 population. In contrast, less than 3% of T3 and T29 were found in the sub-G 0 /G 1 population in the same suspension culture condition. This confirmed our previous finding that TIMP-1 inhibits cell death induced by the loss of cell adhesion. Interestingly, TIMP-1 inhibition of anoikis is accompanied with decreased S phase population and increased cell cycle arrest at G 1 and/or G 2 /M, demonstrating TIMP-1's ability to induce cell cycle in the absence of cell adhesion.
TIMP-1 upregulates p27
KIP1 and downregulates cyclin D 1 expression To further investigate the molecular actions of TIMP-1 for cell cycle regulation, we examined whether TIMP-1 modulates the levels and/or activities of cyclins and TIMP-1 regulation of cell cycle via p27 KIP1 stabilization ME Taube et al cyclin-dependent kinase inhibitors (CDKIs), the functions of which are critical for cell cycle progression. As shown in Figure 3a , TIMP-1 overexpression lead to a significant decrease in the cyclin D 1 level, a G 1 cyclin critical for cell cycle entry and G 1 progression (Motokura and Arnold, 1993; Hatakeyama et al., 1994) , whereas it induced the level of cyclin E1 expression, a late G 1 cyclin critical for the cell cycle progression into the S phase Hinds et al., 1992; Koff et al., 1992) . Since kinase activities of cyclin complexes are regulated by CDKIs, we also examined the effects of TIMP-1 overexpression on CDKI expression. Whereas , p16
INK4a , and b-actin were performed using total cell lysates of MCF10Aneo (Neo), TIMP-1 MCF10A #29 (T29), TIMP-1 MCF10A #3 (T3) cells grown on monolayer. Densitometry analysis of intensity of the p27 KIP1 , cyclin D 1 , cyclin E, p21
INK4a bands was presented as a ratio to the b-actin level in the respective cells. The band intensity in Neo cells was arbitrarily given as 1.0. (b) Neo and T29 cells were grown on the coverslips overnight, blocked with PBS containing 10% horse serum 1% BSA, and stained with control Ab or with anti-p27
KIP1
Ab followed by FITC-conjugated secondary Ab (green), and with DAPI (blue) to counterstain the nuclei.
TIMP-1 regulation of cell cycle via p27 KIP1 stabilization ME Taube et al TIMP-1 had little effect on the levels of p21 WAF1/CIP1 (a universal inhibitor of CDKs) and p16
INK4a (an inhibitor of early G 1 cyclin), TIMP-1 overexpression drastically enhanced the p27 KIP1 levels, a potent CDKI of cell cycle progression from late G 1 to the S phase (Toyoshima and Hunter, 1994; Chen et al., 1995; Luo et al., 1995; Sherr and Roberts, 1995) . These results suggest that TIMP-1-mediated decrease in cell proliferation is associated with its ability to downregulate cyclin D 1 and to upregulate p27 KIP1 . TIMP-1 upregulation of the p27 KIP1 protein is also confirmed by immunoflurescent staining. Confocal analysis revealed that the p27 KIP1 protein is distributed mostly in the cytoplasm but also in the nucleus in TIMP-1 overexpressing cells, whereas the weak staining of the p27 KIP1 protein is almost exclusively found in the nucleus of control cells (Figure 3b) .
We then asked whether exogenous treatment of human breast epithelial cells with recombinant TIMP-1 can also induce p27 KIP1 and/or downregulate cyclin D 1 expression. As shown in Figure 4 , the p27 KIP1 protein level significantly increased following 24 h treatment of AS cells with recombinant tissue inhibitor of metalloproteinase (rTIMP-1), and the 48 h treatment further enhanced its level. Conversely, the same treatment of AS cells with rTIMP-1 significantly downregulated cyclin D 1 (Figure 4) . TIMP-1 induction of p27 KIP1 and its downregulation of cyclin D 1 suggest that TIMP-1 suppresses cyclin dependent kinase (CDK) activity critical for the cell cycle transition. To address this, we examined TIMP-1 modulation of phosphorylation of retinoblastoma (Rb) protein. Rb is phosphorylated by D-type cyclin-dependent kinases and further phosphorylated by cyclin E-and A-dependent kinases, and the maintenance of Rb hyperphosphorylation is critical for the cell cycle progression into the S, G 2 and M phase Dowdy et al., 1993) . As shown in Figure 4 , the level of phosphorylated Rb was significantly reduced following rTIMP-1 treatment in AS cells, which coincides with its induction of p27 KIP1 and downregulation of cyclin D 1 . Interestingly, TIMP-1 modulation of p27 KIP1 and cyclin D 1 levels and the subsequent inhibition of CDK activity appears to be independent of growth factor signaling as shown by its modulation regardless of serum (Figure 4 ).
TIMP-1 modulates the levels of p27
KIP1 and cyclin D 1 via differential regulation of protein stability To examine whether TIMP-1 regulates the mRNA levels of p27 KIP1 and cyclin D 1 , real-time PCR analysis was performed. Surprisingly, the effects of TIMP-1 overexpression on the mRNA levels of p27 KIP1 and cyclin D 1 were opposite of its effects on the protein levels ( Figure 5a ). This suggests that TIMP-1 modulates p27 KIP1 and cyclin D 1 protein levels through either translational or post-translational regulation.
To estimate the protein stability of p27 KIP1 and cyclin D 1 in relation to the expression levels of TIMP-1, the levels of these proteins were examined after treating cells with cycloheximide. As a control, the levels of the tumor suppressor p53 protein, known to have a short half-life, was also examined. As shown in Figure 5b , the p53 levels drastically reduced by half within 1 h and were almost nondetectable after 4 h of treatment, showing that cycloheximide efficiently prevented new protein synthesis. The p27 KIP1 protein level in AS cells decreased to less than 50% in the absence of protein synthesis for 4 h, whereas its level remained the same in TIMP-1 overexpressing T29 cells. Conversely, the cyclin D 1 protein level remained the same in the AS cells in the absence of protein synthesis, whereas its levels were drastically reduced in T29 cells following 1 h cycloheximide treatment. We further showed that when proteasome-mediated protein degradation is inhibited using the proteasome inhibitor MG-132, both p27 KIP1 and cyclin D 1 proteins accumulated regardless of TIMP-1 expression (Figure 5c ). This suggests that TIMP-1-mediated differential regulation of the proteasome pathway is responsible for TIMP-1-mediated differential regulation of p27 KIP1 and cyclin D 1 protein levels. Taken together, the present study showed that endogenously expressed TIMP-1 or exogenously added rTIMP-1 downregulates cyclin D 1 and upregulates Figure 4 rTIMP-1 downregulates cyclin D 1 and upregulates p27 KIP1 expression independent of serum. AS TIMP-1 MCF10A (AS) cells grown on monolayer were treated with 500 ng/ml recombinant TIMP-1 in the absence or presence of serum. Protein extracts were prepared at the indicated time points using RIPA buffer or SDS lysis buffer, and subjected to immunoblotting analysis with the indicated antibodies. Densitometry analysis of intensity of the p27 KIP1 and cyclin D 1 bands were presented as a ratio to the b-actin level in the respective cells. Densitometry analysis of intensity of the pRb (ser795), pRb (ser780), and pRb (ser807/811) were presented as a ratio to the Rb (4H1) level in the respective cells. The band intensity at 0 h was arbitrarily given as 1.0.
TIMP-1 regulation of cell cycle via p27 KIP1 stabilization ME Taube et al p27 KIP1 through differential modulation of protein stability, resulting in inhibition of cyclin-dependent kinase activity critical for cell cycle progression in human breast epithelial cells.
Discussion
The present study showed that TIMP-1 modulates the levels of cyclin D 1 and its inhibitor p27 KIP1 at the posttranslational level, resulting in growth inhibition in human breast epithelial cells. TIMP-1 upregulation of p27 KIP1 is of particular interest in light of previous reports that cell adhesion to fibrillar collagen matrix induces integrin a 2 b 1 -mediated cell adhesion signaling leading to growth inhibition via upregulation of p27 KIP1 , whereas nonfibrillar (denatured) collagen does not transmit a growth regulatory signal (Montgomery et al., 1994; Henriet et al., 2000) . These studies suggested that MMP-mediated fibrillar collagen degradation helps cancer cells escape ECM-mediated growth inhibitory signals (Montgomery et al., 1994; Henriet et al., 1999 Henriet et al., , 2000 . Consistently, TIMPs were suggested to mediate growth inhibitory signal via their inhibition of MMPsmediated ECM degradation, promoting cell adhesion (Montgomery et al., 1994; Henriet et al., 1999 Henriet et al., , 2000 . However, our study suggests that TIMP-1's growth inhibitory activity in MCF10A cells may not depend on its MMP inhibitory activity to promote cell adhesion, since it induces cell cycle arrest even in the absence of cell adhesion following anoikis induction. Interestingly, whereas fibrillar collagen-mediated signaling has no effects on apoptosis in human melanoma cells (Henriet et al., 2000) , TIMP-1 simultaneously regulates cell cycle and apoptosis in human breast epithelial cells, suggesting that TIMP-1-mediated signaling may differ from cell adhesion signaling initiated by cell-ECM contacts.
Both MMP-dependent and -independent TIMP-1 regulations of cell growth have been reported. In a murine liver regeneration model, TIMP-1 was shown to reduce hepatocyte cell proliferation by its inhibition of extracellular proteolytic activation of hepatocyte growth factor (HGF) (Mohammed et al., 2005) . In breast carcinoma MDA-MB-435 cells, TIMP-1 was suggested to promote cell growth through its MMP inhibitory activity, since synthetic MMP inhibitors GM7001 (Galardin) and BB94 (Batimastat) have growth promoting activity similar to TIMP-1 (Porter et al., 2004) . In contrary, studies reported that TIMP-1 can regulate cell growth independent of its MMP inhibitory activity over the past decade (Golde et al., 1980; Docherty et al., 1985; Avalos et al., 1988) . Interestingly, when the sulphydral groups in TIMP-1 were alkylated, this alkylated TIMP-1 failed to inhibit MMPs, but was able to stimulate cell growth in Raji cells, supporting a notion that TIMP-1 possesses a novel cytokine-like activity (Hayakawa et al., 1992) . In accordance, the present study suggests that TIMP-1-specific cell signaling is critical for cell cycle arrest rather than its indirect regulation of growth factor signaling through its MMP inhibitory activity. TIMP-1-mediated upregulation of p27 KIP1 and downregulation of cyclin D 1 were comparable in the serum-free condition and the culture condition with an excess of growth factors (5% horse serum, 10 mg/ml insulin, and 20 ng/ml epidermal growth factor). More importantly, we previously showed that TIMP-1, but neither broad spectrum MMP inhibitor BB94 nor the synthetic peptide hydroxamate metalloproteinase inhibitor/tumor necrosis factor-protease inhibitor (TAPI), had effects on cell growth or death (Liu et al., 2005) , supporting a role for TIMP-1 in cell signaling independent of its MMP-inhibitory activity.
Collectively, it appears that TIMP-1 can regulate cellular processes through both MMP-dependent andindependent manners. In a microenvironment where MMP-mediated growth factor activation, growth factor receptor cleavage or ECM degradation predominantly affects cell growth and death, we can envision TIMP-1's regulation of cell growth and death primarily via MMP inhibition. In a microenvironment where cellular processes are regulated by MMP-independent stimuli, TIMP-1 may be a critical determinant for cell growth and death through its novel activity regulating intracellular signal transduction pathways.
Biochemical studies and animal experiments have clearly shown TIMP-1's tumor-suppressing, antimetastatic effects via its inhibition of matrix degrading enzymes (Liotta et al., 1991; DeClerck et al., 1992) . TIMP-1 regulation of cell cycle via p27 KIP1 stabilization ME Taube et al However, clinical studies showed increased TIMP-1 expression in many human tumors and its increased expression often correlates with poor prognosis (Liotta et al., 1991; DeClerck et al., 1992) , raising an important question regarding TIMP-1's role during tumor progression. Although mounting evidence indicates TIMP-1 is an effective inhibitor of apoptosis in many cell types including activated hepatic stellate cells, erythorid cells, Burkitt's lymphoma cell lines, human breast cell lines and mammary epithelial cells as well as in transgenic mice (Alexander et al., 1996; Guedez et al., 1998a, b; Li et al., 1999; Murphy et al., 2002; Yoshiji et al., 2002; Lee et al., 2003; Liu et al., 2003 Liu et al., , 2005 , conflicting data has been reported regarding TIMP-1's role in cell proliferation. Whereas TIMP-1 is mitogenic in certain cancer cells and lymphoid cells (Bertaux et al., 1991; Hayakawa et al., 1992) , TIMP-1 has growth inhibitory effects on normal mammary epithelial cell proliferation (Fata et al., 1999) . Downregulation of TIMP-1 expression by transgenic AS expression resulted in excessive ductal branches with increased mammary epithelial cell proliferation and ductal expansion. Conversely, slowrelease pellet of recombinant TIMP-1 protein leads to inhibition of ductal elongation with decreased mammary epithelial cell proliferation (Fata et al., 1999) . The present study also showed TIMP-1 reduces cell proliferation rates in nonmalignant human breast epithelial MCF10A cells. In mammary epithelial cells, TIMP-1's effects on apoptosis and cell cycle resemble the antiapoptotic gene product bcl-2, which is a potent apoptosis inhibitor with the ability to retard G 0 to S phase transition in B-and T lymphocytes (Linette et al., 1996; Mazel et al., 1996; O'Reilly et al., 1996) . At present, it is unclear whether TIMP-1's ability to regulate apoptosis depends on its ability to regulate cell cycle or vice versa.
TIMP-1 regulation of cell survival coupled to control of cell cycle arrest might be critical during the early stages of carcinogenesis. Increase in tumor volume inevitably results in an unfavorable microenvironment for cell growth. While cells unable to tolerate hypoxic or mal-nutrient microenvironment become necrotic or apoptotic, cells capable of coordinating the opposing pathways of cell growth and death by simultaneously arresting cell cycle and activating the survival pathway may survive, allowing cells to accumulate genetic changes contributing to oncogenesis.
In summary, the present study provides a molecular insight as to how TIMP-1 regulates cell cycle in nonmalignant human breast epithelial cells. It remains to be fully investigated whether TIMP-1-mediated cell cycle arrest is beneficial for tumor cells to survive, or whether growth inhibitory activity of TIMP-1 simply slows down tumor progression. It should be emphasized that it is critical to evaluate the pleiotropic activities of TIMP-1 in the context of tumor microenvironments, the different stages of tumor progression and the genetic background, considering complex roles of TIMP-1 in the regulation of cell proliferation, apoptosis and metastasis.
Materials and methods

Cell culture
Generation of TIMP-1 overexpressing MCF10A clones #3 and #29 (T3 and T29), AS TIMP-1 construct-transfected MCF10A clone (AS TIMP-1 MCF10A), and control vector-transfected MCF10Aneo (Neo) was described previously (Li et al., 1999; Liu et al., 2003) . Cells were cultured in DMEM/F-12 medium supplemented with 5% horse serum, 0.5 mg/ml hydrocortisone, 10 mg/ml insulin, 20 ng/ml epidermal growth factor, 0.1 mg/ml cholera endotoxin, 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, and 0.5 mg/ml Fungizone in a 95% air and 5% CO 2 incubator at 371C. Cycloheximide and proteasome inhibitor MG 132 were purchased from Sigma (St Louis, MO, USA). Normal donkey serum was purchased from Jackson ImmunoResearch Laboratories Inc (West Grove, PA, USA). DAPI was purchased from Roche Applied Science, (Indianapolis, IN, USA). Human recombinant TIMP-1 was produced using a vaccinia mammalian cell expression system as described previously (Li et al., 1999; Liu et al., 2003) .
Cell proliferation assay (WST-1 assay)
In a 96-well culture plate, 2000 cells were plated and cell viability was determined at the indicated time point by WST-1 assay as specified by the manufacturer (Roche Molecular Biochemicals, Mannheim, Germany). The WST-1 colorimetric assay is based on the cleavage of the tetrazolium salt, WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene di-sulfonate), by mitochondrial dehydrogenases in viable cells to form highly water-soluble formazan without an additional solubilization step. The absorbance of the converted dye was measured at a wavelength of 450 nm, with background subtraction at 650 nm, using a Bio-Rad Benchmark microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).
Detection of cell cycle phase by PI staining 2 Â 10 6 cells were plated in either polyhydroxyethylmethacrylate (polyHEMA)-coated or regular 10 cm tissue culture plates and incubated for 24 h. Cells were harvested, washed once in PBS, centrifuged, and fixed in 100% ethanol for 24 h at 41C. The nuclei were stained with 20 mg/ml propidium iodide (PI) in 1% Triton-X100/PBS containing 200 mg/ml DNase-free RNase, and the DNA content was analysed by flow cytometry using FACSCalibur (Becton Dickinson, San Jose, CA, USA). The percentage of cells in each phase of the cell cycle was determined by Modfit LT program (Verity Software House, Topsham, ME, USA).
Immunoblot analysis
Protein extracts were prepared by lysing the cells with either SDS lysis buffer (2% SDS, 125 mM Tris-HCl (pH 6.8), and TIMP-1 regulation of cell cycle via p27 KIP1 stabilization ME Taube et al 20% glycerol) or modified RIPA buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% deoxycholic acid, 10% Nonidet P-40, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM sodium vanadate, and 50 mM sodium fluoride). Protein concentration was measured using the BCA protein assay reagent (Pierce, Rockford, IL, USA). Equal amount of protein samples in SDS sample buffer (1% SDS, 62.5 mM TrisHCl (pH 6.8), 10% glycerol, 5% b-mercaptoethanol, and 0.05% bromophenol blue) were boiled for 5 min and subjected to reducing SDS-PAGE. After electrophoresis, the proteins were transferred to a nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk in 100 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.02% NaN 3 and 0.2% Tween 20 (T-TBS) for 1 h at room temperature. The membranes were incubated with T-TBS containing 5% milk and in the appropriate antibodies. After three washes with T-TBS, the blot was incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies. The antigen was detected using the Western Blot Chemiluminescence Reagent Plus (PerkinElmer Life Sciences Inc., Boston, MA, USA), according to the manufacturer's instruction.
Immunofluorescent staining
Cells plated on a cover slip were washed three times with PBS containing 1 mM Ca 2 þ and Mg 2 þ (PBS-CM), fixed in 4% paraformaldehyde at room temperature for 20 min, and permeabilized in 0.5% Triton X-100 in PBS for 10 min at 41C. Cells were washed three times with PBS:Glycine buffer (130 mM HCl, 7 mM Na 2 HPO 4 , 3.5 mM NaH 2 PO 4 , 100 mM glycine) for 10 min, blocked with 2% BSA in PBS at RT for 1 h, and washed three times with PBS-CM, followed by incubation with a monoclonal anti-p27 kipÀ1 antibody for 1 h. After three washes with PBS-CM, cells were incubated with FITC-conjugated anti-mouse secondary Ab for 1 h at room temperature in normal donkey serum (NDS) diluted in PBS-CM. After three washes, cells were incubated for 10 min at RT with 4 0 -6-Diamidino-2-phenylindole (DAPI), and mounted with antifade solution overnight in the dark. Confocal fluorescence microscopic analysis was performed using the Zeiss LSM510 confocal microscopy system equipped with krypton-argon (488 and 568 lines) and ultraviolet (364 line) lasers.
Real-time PCR analysis
Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's protocol, and cDNA was synthesized from 2 mg of total RNA. PCR primer pairs were as follows: cyclin D 1 (5 0 -CAGGCTGTGTCCCTCTTCTC-3 0 , 5 0 -CAGAAGCTATTCCAATCATCCC-3 0 ), P27 kipÀ1 (5 0 -AGT TAACCCGGGACTTGGAG-3 0 , 5 0 -GCGTGTCCTCAGAG TTAGCC-3 0 ) and GAPDH (5 0 -ATCACCATCTTCCAGGA GCGA-3, 5 0 -GCCAGTGAGCTTCCCGTTCA-3 0 ). Real-time PCR reactions were carried out using Brilliant SYBR Green QPCR Master Mix (Stratagene, La Jolla, CA, USA), and thermal cycling was carried out on the Mx4000, multiplex quantitative PCR system (Stratagene) using optimized PCR conditions in triplicate. The median cycle threshold value was used for analysis, and all cycle threshold values were normalized to the expression of the housekeeping gene GAPDH.
The mRNA level in Neo cells is arbitrarily given as 1, and the relative mRNA levels in TIMP-1 overexpressing cells (T3 and T29) compared to the levels in the control cells (Neo) were determined as recommended by the manufacturer (Stratagene).
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